Levocarnitine may improve the survival of patients with liver cirrhosis who undergo cell-free and concentrated ascites reinfusion therapy for refractory ascites

DOI Web Site Web Site 4 References Open Access

Bibliographic Information

Other Title
  • 腹水濾過濃縮再静注治療中の肝硬変患者に対するレボカルニチン内服は予後を改善する可能性がある
  • フクスイ ロカ ノウシュク サイジョウチュウ チリョウ チュウ ノ カンコウヘン カンジャ ニ タイスル レボカルニチン ナイフク ワ ヨゴ オ カイゼン スル カノウセイ ガ アル

Search this article

Abstract

<p>Cell-free and concentrated ascites reinfusion therapy (CART) is a therapeutic option against refractory ascites. The clinical outcomes of 294 CART procedures in 53 patients with cirrhosis were evaluated. In median, 5,120 mL of ascites was drained, then filtered and concentrated to 500 mL. Eventually, 56.8 g/dL of proteins (including 25.7 g/dL of albumin) was reinfused in each procedure. The median survival was 79 days. In multivariable analysis, oral levocarnitine administration (hazard ratio, 0.311; 95% confidence interval, 0.140-0.646) was associated with mortality aside from ALBI score and concurrent malignant disease. The median survival in those with and without levocarnitine was 140 days and 38 days, respectively. Levocarnitine may contribute to a favorable prognosis in patients who undergo CART for refractory ascites.</p>

Journal

  • Kanzo

    Kanzo 62 (10), 663-666, 2021-10-01

    The Japan Society of Hepatology

References(4)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top